Expert Outlook: Macrogenics Through The Eyes Of 7 Analysts
Portfolio Pulse from Benzinga Insights
Over the last three months, 7 analysts have shared their evaluations of Macrogenics (NASDAQ:MGNX), showing a range of sentiments from bullish to bearish. The average 12-month price target has declined by 56.5% to $9.57. Analysts have recently lowered their ratings and price targets, reflecting concerns about the company's financial performance and market conditions.
July 29, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have recently lowered their ratings and price targets for Macrogenics, with the average 12-month target now at $9.57, down 56.5%. This reflects concerns about the company's financial performance and market conditions.
The significant reduction in price targets and the lowering of ratings by multiple analysts indicate a bearish outlook on Macrogenics. This is likely to negatively impact the stock price in the short term as investors react to the downgraded expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100